Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort.
Détails
Etat: Public
Version: Final published version
Licence: CC BY-NC-ND 4.0
ID Serval
serval:BIB_7B445915312D
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort.
Périodique
Alzheimer's & dementia
ISSN
1552-5279 (Electronic)
ISSN-L
1552-5260
Statut éditorial
Publié
Date de publication
06/2019
Peer-reviewed
Oui
Volume
15
Numéro
6
Pages
817-827
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Résumé
A critical and as-yet unmet need in Alzheimer's disease (AD) is the discovery of peripheral small molecule biomarkers. Given that brain pathology precedes clinical symptom onset, we set out to test whether metabolites in blood associated with pathology as indexed by cerebrospinal fluid (CSF) AD biomarkers.
This study analyzed 593 plasma samples selected from the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery study, of individuals who were cognitively healthy (n = 242), had mild cognitive impairment (n = 236), or had AD-type dementia (n = 115). Logistic regressions were carried out between plasma metabolites (n = 883) and CSF markers, magnetic resonance imaging, cognition, and clinical diagnosis.
Eight metabolites were associated with amyloid β and one with t-tau in CSF, these were primary fatty acid amides (PFAMs), lipokines, and amino acids. From these, PFAMs, glutamate, and aspartate also associated with hippocampal volume and memory.
PFAMs have been found increased and associated with amyloid β burden in CSF and clinical measures.
This study analyzed 593 plasma samples selected from the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery study, of individuals who were cognitively healthy (n = 242), had mild cognitive impairment (n = 236), or had AD-type dementia (n = 115). Logistic regressions were carried out between plasma metabolites (n = 883) and CSF markers, magnetic resonance imaging, cognition, and clinical diagnosis.
Eight metabolites were associated with amyloid β and one with t-tau in CSF, these were primary fatty acid amides (PFAMs), lipokines, and amino acids. From these, PFAMs, glutamate, and aspartate also associated with hippocampal volume and memory.
PFAMs have been found increased and associated with amyloid β burden in CSF and clinical measures.
Mots-clé
Aged, Amyloid beta-Peptides/blood, Amyloid beta-Peptides/cerebrospinal fluid, Amyloidosis/blood, Amyloidosis/cerebrospinal fluid, Amyloidosis/metabolism, Biomarkers/blood, Biomarkers/cerebrospinal fluid, Brain/pathology, Cognitive Dysfunction/diagnosis, Cohort Studies, Female, Hippocampus/metabolism, Humans, Magnetic Resonance Imaging, Male, Memory/physiology, Metabolomics, Middle Aged, Neuropsychological Tests, tau Proteins/blood, tau Proteins/cerebrospinal fluid, Alzheimer's disease, Amyloid, Biomarkers, Brain volume measurements, CSF, Cognitive function measurements, Dementia, EMIF-AD, Tau
Pubmed
Web of science
Open Access
Oui
Création de la notice
14/05/2019 13:32
Dernière modification de la notice
21/11/2022 8:19
Données d'usage
